An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

BACKGROUND: Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of glucocorticoid-induced diabetes mellitus. METHODS: From De...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Yoshia, Sada, Ken-Ei, Asano, Yosuke, Hayashi, Keigo, Yamamura, Yuriko, Hiramatsu, Sumie, Ohashi, Keiji, Morishita, Michiko, Watanabe, Haruki, Matsumoto, Yoshinori, Sunahori-Watanabe, Katsue, Kawabata, Tomoko, Wada, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171234/
https://www.ncbi.nlm.nih.gov/pubmed/30285859
http://dx.doi.org/10.1186/s13256-018-1817-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171234/
https://www.ncbi.nlm.nih.gov/pubmed/30285859
http://dx.doi.org/10.1186/s13256-018-1817-6

Ejemplares similares